What a COA Is and Who Should Issue It
A Certificate of Analysis is a document provided by a testing laboratory that records the results of quality-control analyses performed on a specific batch of a compound. For research peptides, a COA should accompany every vial and confirm that the product in that vial is what the supplier claims, in terms of identity, purity, and safety parameters.
The critical qualifier is who issues it. A COA carries meaningful assurance only when it is produced by an independent, third-party analytical laboratory — one that has no commercial relationship with the supplier and no financial interest in the outcome of the analysis. A COA generated by the supplier's own internal testing facility is not independent, regardless of how it is presented. When a supplier refers to in-house testing as the basis of their COA, the document is describing internal quality control, not external verification.
The laboratory issuing the COA should be identifiable by name, and ideally should be accredited to ISO 17025 or an equivalent standard for analytical testing. Accreditation is not an absolute requirement for every type of peptide testing, but it indicates that the laboratory's methods and competencies have been assessed by an external body.
HPLC Purity: What the Percentage Means and What Is Acceptable
High-performance liquid chromatography (HPLC) is the standard analytical method for measuring peptide purity. The technique separates the components of a sample as they pass through a column under pressure, allowing the relative proportion of each component to be measured against a detector signal. The purity figure reported, expressed as a percentage, represents the proportion of the detected signal that corresponds to the target compound.
A purity of 98% does not mean that the remaining 2% is inert or safe — it means that 2% of the measured signal consists of something other than the target peptide. Those impurities could be truncated synthesis sequences, residual solvents, degradation products, or contaminating compounds. The higher the purity figure, the less of this unknown content is present.
Research-grade peptides from reputable suppliers typically report HPLC purity of 98% or above. Some high-quality suppliers achieve 99% or higher. Purity figures below 95% are generally considered substandard for research applications, and a COA presenting figures in that range warrants careful evaluation. The test date also matters — HPLC results degrade over time, and a COA with a testing date that predates the current supply chain by a year or more may not reflect the current product.
Mass Spectrometry: Confirming the Molecule Is What the Supplier Claims
HPLC purity confirms the proportion of the target compound in a sample, but it does not independently confirm that the major component is actually the intended peptide. Mass spectrometry (MS) addresses this question by measuring the molecular mass of the compound and comparing it against the known theoretical mass of the target sequence.
A COA for a research peptide should include mass spectrometry data — typically reported as the observed mass versus the expected mass, with a tolerance range. If those numbers match within an acceptable margin (usually within 1 Da or within a specified parts-per-million threshold depending on the instrument), the data supports that the major compound is what is claimed. If the mass is wrong, the compound is either not what it was claimed to be or has undergone degradation.
For a detailed walkthrough of interpreting these measurements in practice, reading a peptide certificate of analysis step by step covers both the HPLC and MS sections with annotated examples.
Endotoxin Testing: The Bacteria-Byproduct Risk Most Buyers Overlook
Endotoxins are lipopolysaccharide fragments released by gram-negative bacteria and represent one of the most significant safety risks in injectable compounds. Even tiny quantities of endotoxin introduced into systemic circulation can trigger a pyrogenic response — fever, chills, and in severe cases, septic shock. This risk is specific to injectable use; endotoxins are not absorbed intact through the oral or topical route.
Endotoxin testing is most commonly performed using the Limulus Amebocyte Lysate (LAL) assay or the recombinant Factor C (rFC) assay. Results are expressed in endotoxin units per milligram (EU/mg). Pharmaceutical-grade injectables are subject to strict endotoxin limits under pharmacopoeial standards, typically well below 5 EU/mg depending on the route and dose.
Many research-grade peptide COAs omit endotoxin testing entirely. The absence of this test on a COA for a compound that is likely to be used by injection is a meaningful gap that buyers should note. A supplier who proactively includes endotoxin data is providing something that distinguishes their quality programme from the minimum.
Sterility Testing: Limits and Why It Matters for Injectable Peptides
Sterility testing determines whether a batch is free from viable microorganisms — bacteria, fungi, and moulds. For pharmaceutical injectables, sterility testing is a compendium requirement. For research peptides, it is far less consistently applied.
The challenge with sterility testing for small-batch research compounds is practical: full compendial sterility tests require incubation over multiple weeks and consume a portion of the batch being tested. Many research suppliers cannot run sterility testing at the batch level without significant commercial cost.
Where sterility data appears on a COA, it should reference a recognised test method (such as USP or equivalent) and record whether the batch passed or failed. Where sterility data is absent, the practical implication is that the user is reconstituting the lyophilised compound in bacteriostatic water under their own conditions, and the sterility of the final solution depends on those conditions as much as on the original batch.
Understanding both what peptide quality testing methods explained and what they cannot tell you is essential to calibrating the risk appropriately.
Red Flags in a COA: In-House Testing, Missing Dates, and Vague Methodology
Several features of a COA should prompt heightened scrutiny rather than acceptance at face value.
Testing conducted by the supplier's own facility rather than an independent third party removes the independence that gives COA data its value. The supplier has a commercial incentive for results to look good; an independent laboratory does not.
Missing or implausible dates are a second concern. A COA without a clearly stated testing date cannot be evaluated for currency. A testing date that predates the lot number or differs from the stated manufacture date by an implausible interval warrants an explanation.
Vague methodology is a third flag. A COA that states "HPLC purity: 99.5%" without specifying the chromatographic method, detector type, column specifications, or mobile phase is presenting a conclusion without a method. Reputable analytical laboratories include method references or full method descriptions as standard. The absence of method detail prevents any external verification of the analysis.
How to Cross-Reference a COA Against a Third-Party Testing Database
Several independent third-party testing initiatives exist for research peptides, most notably community-organised testing programmes where buyers submit samples to independent laboratories and publish the results publicly. These databases allow comparison of results from the same supplier's compounds across multiple batch tests and buying occasions.
Cross-referencing a supplier COA against published third-party test results for the same compound or supplier is one of the most reliable verification methods available to buyers. It does not guarantee that the specific vial being evaluated matches any previously tested batch, but a consistent pattern of third-party results that matches or exceeds supplier COA claims provides meaningful corroborating evidence. A pattern of discrepancy tells a different story: third-party results consistently below supplier COA figures.
